Perioperative and long-term outcomes of utilizing donation after circulatory death liver grafts with macrosteatosis: A multicenter analysis.
clinical research/practice
donors and donation: donation after circulatory death (DCD)
donors and donation: extended criteria
liver transplantation/hepatology
organ procurement and allocation
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
30
11
2019
revised:
04
02
2020
accepted:
10
03
2020
pubmed:
28
3
2020
medline:
22
6
2021
entrez:
28
3
2020
Statut:
ppublish
Résumé
Given the potentially additive risk from using donor livers that are both steatotic and from a donation after circulatory death (DCD) donor, there is a paucity of data on the outcome of DCD liver transplantation (LT) utilizing livers with macrosteatosis. All DCD LT performed at Mayo Clinic-Florida, Mayo Clinic-Arizona, and Mayo Clinic-Rochester from 1999 to 2019 were included (N = 714). Recipients of DCD LT were divided into 3 groups: those with moderate macrosteatosis (30%-60%), mild macrosteatosis (5%-30%), and no steatosis (<5%). Patients with moderate macrosteatosis had a higher rate of postreperfusion syndrome (PRS; 53.9% vs 26.2%; P = .002), postreperfusion cardiac arrest (7.7% vs 0.3%; P < .001), primary nonfunction (PNF; 7.7% vs 1.0%; P = .003), early allograft dysfunction (EAD; 70.8% vs 45.6% and 8.3%; P = .02), and acute kidney injury (AKI; 39.1% vs 19.4%; P = .02) than patients with no steatosis. No difference in any of the perioperative complications was seen between the mild macrosteatosis and the no steatosis groups except for the rate of EAD (56.8% vs 45.6%; P = .04). No difference in ischemic cholangiopathy (IC), vascular thrombosis/stenosis or graft, and patient survival was seen between the 3 groups. DCD donors with mild macrosteatosis < 30% can be utilized with no increase in perioperative complications and similar patient and graft survival compared to DCD donors with no steatosis. When utilizing DCD donors with moderate macrosteatosis higher rates of PRS, PNF, postreperfusion cardiac arrest, EAD, and AKI should be anticipated.
Sections du résumé
BACKGROUND
Given the potentially additive risk from using donor livers that are both steatotic and from a donation after circulatory death (DCD) donor, there is a paucity of data on the outcome of DCD liver transplantation (LT) utilizing livers with macrosteatosis.
METHODS
All DCD LT performed at Mayo Clinic-Florida, Mayo Clinic-Arizona, and Mayo Clinic-Rochester from 1999 to 2019 were included (N = 714). Recipients of DCD LT were divided into 3 groups: those with moderate macrosteatosis (30%-60%), mild macrosteatosis (5%-30%), and no steatosis (<5%).
RESULTS
Patients with moderate macrosteatosis had a higher rate of postreperfusion syndrome (PRS; 53.9% vs 26.2%; P = .002), postreperfusion cardiac arrest (7.7% vs 0.3%; P < .001), primary nonfunction (PNF; 7.7% vs 1.0%; P = .003), early allograft dysfunction (EAD; 70.8% vs 45.6% and 8.3%; P = .02), and acute kidney injury (AKI; 39.1% vs 19.4%; P = .02) than patients with no steatosis. No difference in any of the perioperative complications was seen between the mild macrosteatosis and the no steatosis groups except for the rate of EAD (56.8% vs 45.6%; P = .04). No difference in ischemic cholangiopathy (IC), vascular thrombosis/stenosis or graft, and patient survival was seen between the 3 groups.
CONCLUSION
DCD donors with mild macrosteatosis < 30% can be utilized with no increase in perioperative complications and similar patient and graft survival compared to DCD donors with no steatosis. When utilizing DCD donors with moderate macrosteatosis higher rates of PRS, PNF, postreperfusion cardiac arrest, EAD, and AKI should be anticipated.
Identifiants
pubmed: 32216008
doi: 10.1111/ajt.15877
pii: S1600-6135(22)22562-3
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2449-2456Informations de copyright
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Mateo R, Cho Y, Singh G, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2006;6(4):791-796.
Foley DP, Fernandez LA, Leverson G, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg. 2005;242(5):724-731.
Skaro AI, Jay CL, Baker TB, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery. 2009;146(4): 543-553.
de Vera ME, Lopez-Solis R, Dvorchik I, et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant. 2009;9(4):773-781.
Jay C, Ladner D, Wang E, et al. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-an analysis of the national registry. J Hepatol. 2011;55(4):808-813.
Croome KP, Lee DD, Keaveny AP, Taner CB. Improving national results in liver transplantation using grafts from donation after cardiac death donors. Transplantation. 2016;100(12):2640-2647.
Croome KP, Lee DD, Perry DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. Liver Transpl. 2017;23(3):342-351.
Kollmann D, Sapisochin G, Goldaracena N, et al. Expanding the donor pool: donation after circulatory death and living liver donation do not compromise the results of liver transplantation. Liver Transpl. 2018;24(6):779-789.
Bohorquez H, Seal JB, Cohen AJ, et al. Safety and outcomes in 100 consecutive donation after circulatory death liver transplants using a protocol that includes thrombolytic therapy. Am J Transplant. 2017;17(8):2155-2164.
Dubbeld J, Hoekstra H, Farid W, et al. Similar liver transplantation survival with selected cardiac death donors and brain death donors. Br J Surg. 2010;97(5):744-753.
Mihaylov P, Mangus R, Ekser B, et al. Expanding the donor pool with the use of extended criteria donation after circulatory death livers. Liver Transpl. 2019;25(8):1198-1208.
Laing RW, Scalera I, Isaac J, et al. Liver transplantation using grafts from donors after circulatory death: a propensity score-matched study from a single center. Am J Transplant. 2016;16(6):1795-1804.
Croome KP, Lee DD, Taner CB. The "skinny" on assessment and utilization of steatotic liver grafts: a systematic review. Liver Transpl. 2019;25(3):488-499.
Frongillo F, Lirosi MC, Sganga G, et al. Graft steatosis as a risk factor of ischemic-type biliary lesions in liver transplantation. Transplant Proc. 2014;46(7):2293-2294.
Baccarani U, Adani GL, Isola M, et al. Steatosis of the graft is a risk factor for posttransplantation biliary complications. Transplant Proc. 2009;41:1313.
Croome KP, Lee DD, Croome S, et al. The impact of postreperfusion syndrome during liver transplantation using livers with significant macrosteatosis. Am J Transplant. 2019;19(9):2550-2559.
Ploeg RJ, Dʼalessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation a multivariate analysis. Transplantation. 1993;55:807.
Aggarwal S, Kang Y, Freeman JA, Fortunato FL, Pinsky MR. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc. 1987;19(4 Suppl 3):54-55.
Hilmi I, Horton CN, Planinsic RM, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl. 2008;14(4):504-508.
Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16:943-949.
Croome KP, Wall W, Quan D, et al. Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts. Hepatobiliary Pancreat Dis Int. 2012;11:372-376.
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783-790.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute dialysis quality initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212.
Giesbrandt KJ, Bulatao IG, Keaveny AP, Nguyen JH, Paz-Fumagalli R, Taner CB. Radiologic characterization of ischemic cholangiopathy in donation-after-cardiac-death liver transplants and correlation with clinical outcomes. AJR Am J Roentgenol. 2015;205(5):976-984.
Croome KP, McAlister V, Adams P, Marotta P, Wall W, Hernandez-Alejandro R. Endoscopic management of biliary complications following liver transplantation after donation from cardiac death donors. Can J Gastroenterol. 2012;26(9):607-610.
Croome KP, Mathur AK, Lee DD, et al. Outcomes of donation after circulatory death liver grafts from donors 50 years or Older. Transplantation. 2018;102(7):1108-1114.
Schlegel A, Scalera I, Perera MTPR, et al. Impact of donor age in donation after circulatory death liver transplantation: Is the cutoff "60" still of relevance? Liver Transpl. 2018;24(3):352-362.
Battula N, Bohorquez H, Seal J, et al. Results of high risk donation-after-circulatory death (DCD) donor liver transplants. Am J Transplant. 2017;17(S2):19.
Xia W, Ke Q, Wang Y, et al. Donation after cardiac death liver transplantation: graft quality evaluation based on pretransplant liver biopsy. Liver Transpl. 2015;21(6):838-846.
Zhang WJ, Xia WL, Pan HY, Zheng SS. Postreperfusion hyperkalemia in liver transplantation using donation after cardiac death grafts with pathological changes. Hepatobiliary Pancreat Dis Int. 2016;15(5):487-492.
Chadha RM, Croome KP, Aniskevich S, et al. Intraoperative events in liver transplantation using donation after cardiac death donors. Liver Transpl. [Epub ahead. of print]; 2019.
Pan X, Apinyachon W, Xia W, et al. Perioperative complications in liver transplantation using donation after cardiac death grafts: a propensity-matched study. Liver Transpl. 2014;20(7):823-830.
Zalunardo MP, Schlapfer M, Beck-Schimmer B, Seifert B, Spahn DR, Bettex D. Impact of cytokine release on ventricular function after hepatic reperfusion: a prospective observational echocardiographic study with tissue Doppler imaging. BMC Anesthesiol. 2015;15:107.
Nakasuji M, Bookallil MJ. Pathophysiological mechanisms of postrevascularization hyperkalemia in orthotopic liver transplantation. Anesth Analg. 2000;91(6):1351-1355.
Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation. 1999;68(6):780-784.
Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation. 1999;67(2):195-200.
Lee DD, Singh A, Burns JM, Perry DK, Nguyen JH, Taner CB. Early allograft dysfunction in liver transplantation with donation after cardiac death donors results in inferior survival. Liver Transpl. 2014;20(12):1447-1453.